Gary Ferguson
Pulmonary Disease · Livonia, MINPI 1922016385
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by GSK at 41.9% of the total. Reporting peaked in 2019 at $300,319 and has fallen 93.5% since, to $19,455 in 2023. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 611 payments — averaging $983.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$252K
- AstraZeneca$77K
- Boehringer Ingelheim$69K
- Mylan Specialty L.p.$60K
- Astrazeneca UK Limited$43K
- Boehringer Ingelheim International GmbH$35K
- plus $65K from 7 others
Across 89 payments — averaging $10,611 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$319K
- GSK$272K
- Novartis$93K
- AstraZeneca$81K
- Astrazeneca AB$73K
- Chiesi USA, Inc.$47K
- plus $59K from 3 others
What the payments were for
- Consulting fees$175,55929%
- Speaking & faculty fees$338,33156%
- Travel & lodging$76,02913%
- Food & beverage$10,6852%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 235 | $251,937 |
| AstraZeneca | 87 | $76,785 |
| Boehringer Ingelheim | 69 | $68,768 |
| Mylan Specialty L.p. | 88 | $60,423 |
| Astrazeneca UK Limited | 43 | $43,059 |
| Boehringer Ingelheim International GmbH | 20 | $34,572 |
| CSL Behring | 7 | $14,305 |
| Astrazeneca AB | 21 | $13,336 |
| Mylan Inc. | 11 | $10,447 |
| Novartis | 14 | $10,393 |
| Teva Pharmaceuticals USA, Inc. | 4 | $8,145 |
| Sunovion Pharmaceuticals Inc. | 11 | $7,874 |
| Viiv Healthcare Company | 1 | $600 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$195,193
- Yupelri$70,049
- STIOLTO RESPIMAT$35,769
- STIOLTO$31,602
- BEVESPI AEROSPHERE$30,306
- BREZTRI AEROSPHERE$17,735
- BREZTRI$16,175
- ANORO ELLIPTA$15,155
- Zemaira$14,179
- ANORO$10,458
- FASENRA$9,548
- NUCALA$8,613
- LONHALA MAGNAIR$7,806
- ProAir Digihaler$7,205
- SPIRIVA$5,265
- PULMICORT RESPULES$1,635
- AIRSUPRA$1,611
- QBW251$560
How this compares
$600,644 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Livonia
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
- Ihab DeebajahGarden City$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.